Featured Research

from universities, journals, and other organizations

Antiviral therapy may prevent liver cancer in hepatitis B patients

Date:
June 9, 2014
Source:
Henry Ford Health System
Summary:
Researchers have found that antiviral therapy may be successful in preventing hepatitis B virus from developing into the most common form of liver cancer, hepatocellular carcinoma. "The results of this study allow us to reassure our patients that we are not just treating their viral levels, but that antiviral therapy may actually lessen their chance of developing liver cancer," said the study's lead investigator.

Researchers have found that antiviral therapy may be successful in preventing hepatitis B virus from developing into the most common form of liver cancer, hepatocellular carcinoma (HCC).

That was the finding of a study published in the May issue of Clinical Gastroenterology and Hepatology. Investigators from Henry Ford Health System in Detroit, Geisinger Health System in Danville, Pa., and Kaiser Permanente in Honolulu, Hawaii and Portland, Ore. participated in the study, along with investigators from the Centers for Disease Control and Prevention in Atlanta.

According to the first-of-its-kind analysis of more than 2,600 adult participants with hepatitis B, those treated with antiviral therapy had a significantly lower occurrence of HCC during a five-year follow up period. Overall, 3 percent of patients developed HCC during the study's timeframe. But patients who received antiviral therapy were 60 percent less likely to develop HCC than untreated patients.

"The results of this study allow us to reassure our patients that we are not just treating their viral levels, but that antiviral therapy may actually lessen their chance of developing liver cancer," said the study's lead investigator, Henry Ford Health System's Stuart C. Gordon, M.D., who worked closely with Henry Ford Senior Scientist Mei Lu in Detroit.

HCC accounts for the most liver cancers in the United States, typically occurs in people age 50 or older and is more common in men. If the cancer cannot be removed, it is usually fatal in three to six months. In most cases, HCC is caused by scarring in the liver -- cirrhosis -- which can be a result of alcohol abuse, hepatitis B or C, chronic inflammation of the liver or an iron overload.

"This study was one of the first to address antiviral therapy and its efficacy in preventing hepatitis B from developing into liver cancer," said Joseph Boscarino, Ph.D., senior scientist and investigator for the Geisinger site. "With this information, clinicians can begin to prescribe antiviral therapy for hepatitis B patients with the goal of preventing a common and dangerous form of cancer."


Story Source:

The above story is based on materials provided by Henry Ford Health System. Note: Materials may be edited for content and length.


Journal Reference:

  1. Stuart C. Gordon, Lois E. Lamerato, Loralee B. Rupp, Jia Li, Scott D. Holmberg, Anne C. Moorman, Philip R. Spradling, Eyasu H. Teshale, Vinutha Vijayadeva, Joseph A. Boscarino, Emily M. Henkle, Nancy Oja–Tebbe, Mei Lu. Antiviral Therapy for Chronic Hepatitis B Virus Infection and Development of Hepatocellular Carcinoma in a US Population. Clinical Gastroenterology and Hepatology, 2014; 12 (5): 885 DOI: 10.1016/j.cgh.2013.09.062

Cite This Page:

Henry Ford Health System. "Antiviral therapy may prevent liver cancer in hepatitis B patients." ScienceDaily. ScienceDaily, 9 June 2014. <www.sciencedaily.com/releases/2014/06/140609153516.htm>.
Henry Ford Health System. (2014, June 9). Antiviral therapy may prevent liver cancer in hepatitis B patients. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2014/06/140609153516.htm
Henry Ford Health System. "Antiviral therapy may prevent liver cancer in hepatitis B patients." ScienceDaily. www.sciencedaily.com/releases/2014/06/140609153516.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins